Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2010

01-12-2010 | Progress in Hematology

Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia

Author: Ritsuro Suzuki

Published in: International Journal of Hematology | Issue 5/2010

Login to get access

Abstract

Extranodal NK/T cell lymphoma, nasal type (ENKL) with advanced stage and aggressive NK-cell leukemia (ANKL) are highly aggressive neoplasms with a dismal clinical outcome. It is well known that P-glycoprotein, which is a product of MDR1 gene and related to multi-drug resistance, is expressed on tumor cells of ENKL or ANKL. This is a major reason for the refractoriness to conventional chemotherapeutic regimens for malignant lymphoma containing anthracycline. However, recent studies have identified that several drugs including l-asparaginase, methotrexate and alkylators show excellent effect for these tumors. The SMILE (steroid, methotrexate, ifosfamide, l-asparaginase and etoposide) regimen is one of the promising regimens for advanced or relapsed/refractory ENKL, but its myelotoxicity is strong. ANKL needs another treatment strategy because of a systemic disease progression and extensive organ insufficiency. Optimal treatment scheme using such effective agents for these unfavorable NK-cell tumors should further be explored.
Literature
1.
Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood. 1996;87:1207–10.PubMed
2.
3.
Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26:66–72.PubMedCrossRef
4.
Chan JKC, Quintanilla-Martinez L, Ferry JA. Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 285–8.
5.
Chan JKC, Jaffe ES, Ralfkiaer E, Ko Y-H. Aggressive NK-cell leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 276–7.
6.
Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351–6.PubMedCrossRef
7.
Egashira M, Kawamata N, Sugimoto K, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599–606.PubMed
8.
Trambas C, Wang Z, Cianfriglia M, Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol. 2001;114:177–84.PubMedCrossRef
9.
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6.PubMedCrossRef
10.
Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J. l-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78:163–7.PubMedCrossRef
11.
Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99:1016–20.PubMedCrossRef
12.
Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, et al. l-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009;20:110–6.PubMedCrossRef
13.
Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood. 2004;103:216–21.PubMedCrossRef
14.
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612–8.PubMedCrossRef
15.
Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type. Ann Oncol. 2010;21:1032–40.PubMedCrossRef
16.
Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol. 1995;13:666–70.PubMed
17.
Cheung MMC, Chan JKC, Lau WH, Foo W, Chan PT, Ng CS, et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70–7.PubMed
18.
Li YX, Coucke PA, Li JY, Gu DZ, Liu XF, Zhou LQ, et al. Primary non-Hodgkin’s lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998;83:449–56.PubMedCrossRef
19.
Kawa K. Diagnosis and treatment of Epstein–Barr virus-associated natural killer cell lymphoproliferative disease. Int J Hematol. 2003;78:24–31.PubMedCrossRef
20.
Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop. 2005;45:51–70.CrossRef
21.
Nagafuji K, Fujisaki T, Arima F, Ohshima K. l-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001;74:447–50.PubMedCrossRef
22.
Obama K, Tara M, Niina K. l-Asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol. 2003;78:248–50.PubMedCrossRef
23.
Matsumoto Y, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K, et al. Successful treatment with Erwinia l-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma. 2003;44:879–82.PubMedCrossRef
24.
Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130:860–8.PubMedCrossRef
25.
Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphatic leukaemia—still to be defined? Br J Haematol. 2004;125:117–27.PubMedCrossRef
26.
27.
Jaccard A, Gachard N, Coppo P, Morschhauser F, Galicier L, Ysebaert L, et al. A prospective phase II trial of an l-Asparaginase containing regimen in patients with refractory or relapsing extranodal NK/T-cell lymphoma. Blood 2008; 112:217a (Abstract #579).
28.
Yazawa Y, Takagi T, Asakura S, Suzuki K, Kano Y. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. J Orthop Sci. 1999;4:231–7.PubMedCrossRef
29.
Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia. 2002;16:1808–17.PubMedCrossRef
30.
Yamaguchi M, Kwong Y, Maeda Y, Hashimoto C, Kim W, Suh C, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. J Clin Oncol 2010; 28:584s (Abstract #8044).
31.
Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763–70.PubMedCrossRef
32.
Nakashima Y, Tagawa H, Suzuki R, Karnan S, Karube K, Ohshima K, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: Different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44:247–55.PubMedCrossRef
33.
34.
Metadata
Title
Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia
Author
Ritsuro Suzuki
Publication date
01-12-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0726-2

Other articles of this Issue 5/2010

International Journal of Hematology 5/2010 Go to the issue

Case Report

Acute glomerulonephritis in a donor as a side effect of allogeneic peripheral blood stem cell mobilization with granulocyte colony-stimulating factor

Letter to the Editor

A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months

Progress in Hematology

Natural killer cell neoplasm: biology and pathology

Original Article

Secondary antifungal prophylaxis in hematological malignancies in a tertiary medical center

Case Report

Precursor B cell lymphoblastic lymphoma presenting as a solitary bone tumor: a case report and review of the literature

Case Report

Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits